FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890168201> ?p ?o ?g. }

• W2890168201 endingPage "24.e2" @default.
• W2890168201 startingPage "14" @default.
• W2890168201 abstract "Advancement in the diagnosis and treatment of pediatric acute lymphoblastic leukemia (ALL) is one of the greatest successes of modern medicine. Over the past 50 years, there has been a rapid increase in overall survival for pediatric ALL (Figure 1). Several factors have led to these remarkable improvements. First is the development of risk-adapted therapy based on both clinical and biological presenting features, as well as early response to treatment. 2 Pui C.H. Yang J.J. Hunger S.P. Pieters R. Schrappe M. Biondi A. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015; 33: 2938-2948 Crossref PubMed Scopus (170) Google Scholar Second, the effectiveness of molecularly targeted agents for specific genetic abnormalities has boosted outcomes for some high-risk groups. 2 Pui C.H. Yang J.J. Hunger S.P. Pieters R. Schrappe M. Biondi A. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015; 33: 2938-2948 Crossref PubMed Scopus (170) Google Scholar Third, international collaboration among clinical trial networks has led to standardization of definitions and reporting of results, allowing comparison of data across multiple national study groups to identify optimal treatments (Table; available at www.jpeds.com). 2 Pui C.H. Yang J.J. Hunger S.P. Pieters R. Schrappe M. Biondi A. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015; 33: 2938-2948 Crossref PubMed Scopus (170) Google Scholar , 3 Möricke A. Zimmermann M. Valsecchi M.G. Stanulla M. Biondi A. Mann G. et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016; 127: 2101-2112 Crossref PubMed Scopus (36) Google Scholar , 4 Larsen E.C. Devidas M. Chen S. Salzer W.L. Raetz E.A. Loh M.L. et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group study AALL0232. J Clin Oncol. 2016; 34: 2380-2388 Crossref PubMed Scopus (44) Google Scholar , 5 Place A.E. Stevenson K.E. Vrooman L.M. Harris M.H. Hunt S.K. O'Brien J.E. et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015; 16: 1677-1690 Abstract Full Text Full Text PDF PubMed Google Scholar , 6 Domenech C. Suciu S. De Moerloose B. Mazingue F. Plat G. Ferster A. et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014; 99: 1220-1227 Crossref PubMed Scopus (0) Google Scholar , 7 Stary J. Zimmermann M. Campbell M. Castillo L. Dibar E. Donska S. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014; 32: 174-184 Crossref PubMed Scopus (93) Google Scholar , 8 Toft N. Birgens H. Abrahamsson J. Griškevičius L. Hallböök H. Heyman M. et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018; 32: 606-615 Crossref PubMed Scopus (0) Google Scholar , 9 Escherich G. Horstmann M.A. Zimmermann M. Janka-Schaub G.E Cooperative Study Group for Childhood Acute Lymphoblastic Leukaemia (COALL): long-term results of Trials 82, 85, 89, 92, and 97. Leukemia. 2010; 24: 298-308 Crossref PubMed Scopus (0) Google Scholar , 10 Pieters R. de Groot-Kruseman H. Van der Velden V. Fiocco M. van den Berg H. de Bont E. et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016; 34: 2591-2601 Crossref PubMed Scopus (46) Google Scholar , 11 Yamaji K. Okamoto T. Yokota S. Watanabe A. Horikoshi Y. Asami K. et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer. 2010; 55: 1287-1295 Crossref PubMed Scopus (0) Google Scholar , 12 Yeoh A.E. Ariffin H. Chai E.L. Kwok C.S. Chan Y.H. Ponnudurai K. et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012; 30: 2384-2392 Crossref PubMed Scopus (45) Google Scholar , 13 Vora A. Goulden N. Mitchell C. Hancock J. Hough R. Rowntree C. et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15: 809-818 Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar , 14 Pui C.H. Pei D. Coustan-Smith E. Jeha S. Cheng C. Bowman W.P. et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015; 16: 465-474 Abstract Full Text Full Text PDF PubMed Google Scholar , 15 Pui C.H. Campana D. Pei D. Bowman W.P. Sandlund J.T. Kaste S.C. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741 Crossref PubMed Scopus (610) Google Scholar , 16 Li M.J. Liu H.C. Yen H.J. Jaing T.H. Lin D.T. Yang C.P. et al. Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation. Pediatr Blood Cancer. 2017; 64: 234-241 Crossref PubMed Scopus (3) Google Scholar , 17 Schrappe M. Camitta B. Pui C.H. Eden T. Gaynon P. Gustafsson G. et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000; 14: 2193-2194 Crossref PubMed Scopus (0) Google Scholar , 18 Schrappe M. Nachman J. Hunger S. Schmiegelow K. Conter V. Masera G. et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000). Leukemia. 2010; 24: 253-254 Crossref PubMed Scopus (32) Google Scholar Today, the long-term survival rate for pediatric ALL is approaching 90% in many high-income countries, the highest of any type of leukemia in either children or adults. 19 Pui C.H. Evans W.E. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013; 50: 185-196 Abstract Full Text Full Text PDF PubMed Scopus (96) Google Scholar These remarkable achievements notwithstanding, a number of challenges in ALL pathology and treatment remain to be addressed. Relapse still occurs in 10%-15% of patients, and death due to relapsed ALL remains one of the leading causes of cancer mortality in children. Conventional cytotoxic chemotherapy continues to be associated with both short- and long-term toxic effects and is unlikely to be modified substantially in the near future. Thus, it will be important to take advantage of emerging molecular and immunologic insights to improve risk stratification and devise targeted therapies to avoid overtreatment or undertreatment." @default.
• W2890168201 created "2018-09-27" @default.
• W2890168201 creator A5018363328 @default.
• W2890168201 creator A5088402992 @default.
• W2890168201 date "2018-12-01" @default.
• W2890168201 modified "2023-10-18" @default.
• W2890168201 title "Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia" @default.
• W2890168201 cites W1578561002 @default.
• W2890168201 cites W1578918795 @default.
• W2890168201 cites W1864684674 @default.
• W2890168201 cites W1911918948 @default.
• W2890168201 cites W1921422688 @default.
• W2890168201 cites W1945175502 @default.
• W2890168201 cites W1965856472 @default.
• W2890168201 cites W1970504500 @default.
• W2890168201 cites W1973751980 @default.
• W2890168201 cites W1975136907 @default.
• W2890168201 cites W1979259896 @default.
• W2890168201 cites W1984065010 @default.
• W2890168201 cites W1984879354 @default.
• W2890168201 cites W1985198478 @default.
• W2890168201 cites W1990147363 @default.
• W2890168201 cites W1994568187 @default.
• W2890168201 cites W1995246501 @default.
• W2890168201 cites W1996885535 @default.
• W2890168201 cites W1998534364 @default.
• W2890168201 cites W2000266274 @default.
• W2890168201 cites W2000589976 @default.
• W2890168201 cites W2004652425 @default.
• W2890168201 cites W2015018636 @default.
• W2890168201 cites W2016833582 @default.
• W2890168201 cites W2018769121 @default.
• W2890168201 cites W2028104399 @default.
• W2890168201 cites W2033397751 @default.
• W2890168201 cites W2033560619 @default.
• W2890168201 cites W2038978021 @default.
• W2890168201 cites W2040329520 @default.
• W2890168201 cites W2047597898 @default.
• W2890168201 cites W2047965845 @default.
• W2890168201 cites W2048983861 @default.
• W2890168201 cites W2058058260 @default.
• W2890168201 cites W2059999488 @default.
• W2890168201 cites W2060244206 @default.
• W2890168201 cites W2060580006 @default.
• W2890168201 cites W2060605982 @default.
• W2890168201 cites W2063662864 @default.
• W2890168201 cites W2069709802 @default.
• W2890168201 cites W2071899049 @default.
• W2890168201 cites W2079675818 @default.
• W2890168201 cites W2082189475 @default.
• W2890168201 cites W2084781910 @default.
• W2890168201 cites W2089583676 @default.
• W2890168201 cites W2089928288 @default.
• W2890168201 cites W2093101127 @default.
• W2890168201 cites W2095746088 @default.
• W2890168201 cites W2096336184 @default.
• W2890168201 cites W2096709475 @default.
• W2890168201 cites W2104722860 @default.
• W2890168201 cites W2105345844 @default.
• W2890168201 cites W2109000403 @default.
• W2890168201 cites W2116650345 @default.
• W2890168201 cites W2118796952 @default.
• W2890168201 cites W2119093632 @default.
• W2890168201 cites W2119685895 @default.
• W2890168201 cites W2125277492 @default.
• W2890168201 cites W2127090352 @default.
• W2890168201 cites W2127226843 @default.
• W2890168201 cites W2130011407 @default.
• W2890168201 cites W2131206723 @default.
• W2890168201 cites W2138883729 @default.
• W2890168201 cites W2139969490 @default.
• W2890168201 cites W2141414884 @default.
• W2890168201 cites W2141962126 @default.
• W2890168201 cites W2142226489 @default.
• W2890168201 cites W2144921015 @default.
• W2890168201 cites W2147852317 @default.
• W2890168201 cites W2148202982 @default.
• W2890168201 cites W2149078110 @default.
• W2890168201 cites W2149483503 @default.
• W2890168201 cites W2151645052 @default.
• W2890168201 cites W2154410907 @default.
• W2890168201 cites W2157249349 @default.
• W2890168201 cites W2158927044 @default.
• W2890168201 cites W2166306614 @default.
• W2890168201 cites W2167086064 @default.
• W2890168201 cites W2168109746 @default.
• W2890168201 cites W2261300202 @default.
• W2890168201 cites W2278884777 @default.
• W2890168201 cites W2295859676 @default.
• W2890168201 cites W2303408208 @default.
• W2890168201 cites W2311406774 @default.
• W2890168201 cites W2312804644 @default.
• W2890168201 cites W2328983932 @default.
• W2890168201 cites W2342769258 @default.
• W2890168201 cites W2351547314 @default.
• W2890168201 cites W2369297677 @default.
• W2890168201 cites W2400439118 @default.
• W2890168201 cites W2401536218 @default.

• next